Subject: An evolution in treatment - including savings and support.
From: "The Here to Help Team" <heretohelp@suboxone.com>
Date: 10/12/10, 20:29
To: barriticus@gmail.com
Reply-To:
heretohelp@suboxone.com

  You are receiving this e-mail because you signed up for ongoing communications from Reckitt Benckiser Phamaceuticals Inc.

To ensure delivery of future communications, please add heretohelp@suboxone.com to your address book.

If you don't want to get e-mail communications from us in the future, you can opt out.

Here to Help, Supporting you through treatment
Bring SUBOXONE Film into your life—and save.

When you're working to overcome a complex condition like opioid dependence, it helps to have support. That's why SUBOXONE Film comes with built-in support to help you connect with counseling and stay focused on your treatment goals.

SUBOXONE Film, a new formulation of SUBOXONE, may improve your daily treatment experience.

SUBOXONE Film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan that includes counseling and support.

SUBOXONE Film delivers:

An evolved patient experience
-Faster to dissolve than SUBOXONE Tablet1b
-A favorable taste rating (more than 71% of patients scored the taste as neutral or better)1c
-Individually wrapped in compact unit-dose pouches that are child-resistant1d and easy to carry1e
-Once-daily dosing (just like the SUBOXONE Tablet)2
-Clinically interchangeable with SUBOXONE Tablet, so your doctor can transition you. Your doctor should monitor you for overmedication3
Built-in support from the Here to Help® Program that can help make treatment success more likely4

Start saving on your SUBOXONE Film prescription
Simply download your savings card now, and bring it to your next doctor appointment. If eligible, you'll save up to $75* on each SUBOXONE Film prescription you fill, now through March 31, 2011. (Limit one prescription per month.)
*Click here for details

Make an appointment today
To save on SUBOXONE Film, you'll need a SUBOXONE Film prescription. So make an appointment with your doctor today, and ask whether you can improve your treatment experience by choosing SUBOXONE Film.

Remember, opioid dependence is more than a medical condition. Your relationships, thoughts, and daily routines are all tied together. That's why counseling is such a critical part of your treatment. And why support from the Here to Help Program could be too. Here to Help has been shown to increase the likelihood you'll stay in medication-assisted treatment, which can help lead to better treatment success.4

You should know: As with other opioids, buprenorphine can be abused. It's essential that your doctor monitor your use of SUBOXONE Film to help you achieve and maintain stability. You should also expect to make regular follow-up visits, especially if your doctor prescribes multiple refills.

The Here to Help Program is only for people who are in treatment with SUBOXONE Film.

Share
Know someone who is opioid dependent? Help them start their own treatment story. Tell them about SUBOXONE Film.

Best regards,

The Here to Help Team

866-973-HERE (4373)

Important Safety Information

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support. Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

SUBOXONE® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence.

SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets should not be used by patients hypersensitive to buprenorphine or naloxone.

SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient's level of stability is essential.

Chronic use of buprenorphine can cause physical dependence. A sudden or rapid decrease in dose may result in an opioid withdrawal syndrome that is typically milder than seen with full agonists and may be delayed in onset.

SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets can cause serious life-threatening respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to self-administer nonprescribed benzodiazepines or other CNS depressants while taking SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets. Dose reduction of CNS depressants, SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets, or both when both are being taken should be considered.

Liver function should be monitored before and during treatment.

Death has been reported in nontolerant, nondependent individuals, especially in the presence of CNS depressants.

Children who take SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Keep SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets out of the sight and reach of children.

Intravenous misuse or taking SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets before the effects of full-agonist opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided is highly likely to cause opioid withdrawal symptoms.

Neonatal withdrawal has been reported. Use of SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets in pregnant women or during breast-feeding should only be considered if the potential benefit justifies the potential risk. Caution should be exercised when driving vehicles or operating hazardous machinery, especially during dose adjustment.

Adverse events commonly observed during clinical trials and postmarketing experience for SUBOXONE Sublingual Tablets are headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, and swelling of the limbs.

Adverse events commonly observed with the sublingual administration of SUBOXONE Sublingual Film are numb mouth, sore tongue, redness of the mouth, headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, swelling of the limbs, disturbance of attention, palpitations, and blurred vision.

Cytolytic hepatitis, jaundice, and allergic reactions, including anaphylactic shock, have been reported.

This is not a complete list of potential adverse events associated with SUBOXONE Sublingual Film and SUBOXONE Sublingual Tablets. Please see full Product Information for a complete list.

To report an adverse event associated with taking SUBOXONE Sublingual Film or SUBOXONE Sublingual Tablets, please call 1-877-782-6966. You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Product Information and Medication Guide for SUBOXONE Film

For more about SUBOXONE Tablet, please see full Product Information


Take your next step today Download your savings card! Ask about making the transition to SUBOXONE Film. Need help getting the conversation started? Get the discussion guide Find a doctor certified to treat opioid dependence in the privacy of his or her office
Comparisons are between SUBOXONE® (buprenorphine and naloxone) sublingual tablets (CIII) and SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII).

1. Data on file. Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA:

a. Patient preferred: Clinical trial participants preferred SUBOXONE Film over the SUBOXONE Tablet. Results from a questionnaire collected at discharge of a 13-week, multicenter, open-label safety trial. Patients were asked, "Based on your previous experience with SUBOXONE Tablets and your current experience with SUBOXONE Film, which product do you prefer?"
b. Dissolve time: The time required for both SUBOXONE Film and SUBOXONE Tablet dissolution is dependent on saliva quantity and is subject to individual variation, and dose and strength taken. Mean dissolution time for all doses tested (8 mg, 2 mg) was between 5 and 6.6 minutes for SUBOXONE Film and between 7 and 12.4 minutes for the SUBOXONE Tablet.
c. Taste: In a patient questionnaire, more than 71% of patients who have tried SUBOXONE Film rated the taste as neutral or better on a 10-point scale. Results from a questionnaire collected at discharge of a 13-week, multicenter, open-label safety trial. Patients were asked, "Please give this product (SUBOXONE Film) a score which shows how you would rate the flavor." 10=extremely pleasant and 1=extremely unpleasant.
d. Child resistance: Meets the Consumer Product Safety Commission's standards for child resistance. During testing, one child out of 50 was able to open 2 or more pouches. After receiving instruction, the children's ability to open the pouches increased. It is important not to open the pouches in front of children.
e. Portability: Because each unit of SUBOXONE Film is individually packaged in a compact, child-resistant pouch, it's easy to carry with you. Remember to keep this medication out of the sight and reach of children, and take your prescription label along with you. If a child takes the medication, seek emergency care.
2. SUBOXONE Sublingual Film [package insert]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; August 2010.

3. Data on file, Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA.

4. Opioid-dependent patients who were on Buprenorphine-Medication Assisted Therapy (B-MAT) and engaged in the Here to Help Program (completed 4 or more Care Coach calls) demonstrated improved adherence compared to control group for B-MAT. Data on file, Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA.

Unsubscribe  |  Privacy Promise  |  Terms of Use  |  Product Information

If you don't want to get e-mail communications from us in the future, you can opt out.

This communication is sponsored by Reckitt Benckiser Pharmaceuticals Inc.
and intended for residents of the United States.

SUBOXONE® and Here to Help® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.

SUBOXONE Film is manufactured for Reckitt Benckiser
Pharmaceuticals Inc., Richmond, VA 23235 by
MonoSol RX LLC, Warren, NJ 07059.

Copyright © 2010 Reckitt Benckiser Pharmaceuticals Inc.

Reckitt Benckiser Pharmaceuticals Inc.
10710 Midlothian Turnpike
Richmond, VA 23235

The information in this e-mail is provided for educational and informational purposes only and is not intended as a substitute for direct consultation with a qualified health professional.

Reckitt Benckiser Pharmaceuticals Inc.